| abstract |
A pharmaceutical formulation comprising a compound of formula (I), for treatment, in particular a compound of formula (I) for use in the treatment of diseases mediated by CDK2 activity, such as alopecia due to cancer chemotherapy or radiotherapy.n n n <Formula I>n n n n n n n n Wheren n n X is N, CH, CCF 3 , or C (C 1-12 aliphatic);n n n R 4 is sulfonic acid, C 1-12 aliphatic-sulfonyl, sulfonyl-C 1-12 aliphatic, C 1-12 aliphatic-sulfonyl-C 1-6 aliphatic, C 1-6 aliphatic-amino, R 7 -sul Ponyl, R 7 -sulfonyl-C 1-12 aliphatic, R 7 -aminosulfonyl, R 7 -aminosulfonyl-C 1-12 aliphatic, R 7 -sulfonylamino, R 7 -sulfonylamino-C 1 -12 aliphatic, amino, sulfonyl, amino, di -C 1-12 aliphatic amino, di -C 1-12 aliphatic aminocarbonyl, di -C 1-12 aliphatic aminosulfonyl, di -C 1-12 aliphatic amino, di -C 1-12 aliphatic aminocarbonyl, di-C 1-12 aliphatic aminosulfonyl-C 1-12 aliphatic, (R 8 ) 1-3 -arylamino, (R 3 ) 1-3 -arylsulfonyl, (R 8 ) 1-3 -aryl-aminosulfonyl, (R 8 ) 1-3 -aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoimino Aminosulfonyl;n n n R 5 is hydrogen;n n n Or R 4 and R 5 are optionally linked to form a fused ring. |